A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer

Br J Cancer. 2005 May 23;92(10):1834-6. doi: 10.1038/sj.bjc.6602591.


The value of an inflammation-based prognostic score (Glasgow Prognostic score, GPS) was compared with performance status (ECOG-ps) in a longitudinal study of patients (n=101) with inoperable non-small-cell lung cancer (NSCLC). At diagnosis, stratified for treatment, only the GPS (HR 2.32, 95% CI 1.52-3.54, P<0.001) was a significant predictor of survival. In contrast, neither the GPS nor ECOG-ps measured at 3-6 months follow-up were significant predictors of residual survival. This study confirms the prognostic value of the GPS, at diagnosis, in patients with inoperable NSCLC. However, the role of the GPS and ECOG-ps during follow-up has not been established.

MeSH terms

  • Aged
  • Carcinoma, Non-Small-Cell Lung / pathology*
  • Female
  • Health Status
  • Humans
  • Inflammation / classification*
  • Lung Neoplasms / pathology*
  • Male
  • Middle Aged
  • Neoplasm Staging / methods*
  • Prognosis
  • Prospective Studies
  • Survival Analysis